EP1423419B1 - Hybrid and tandem expression of neisserial proteins - Google Patents

Hybrid and tandem expression of neisserial proteins Download PDF

Info

Publication number
EP1423419B1
EP1423419B1 EP02777592A EP02777592A EP1423419B1 EP 1423419 B1 EP1423419 B1 EP 1423419B1 EP 02777592 A EP02777592 A EP 02777592A EP 02777592 A EP02777592 A EP 02777592A EP 1423419 B1 EP1423419 B1 EP 1423419B1
Authority
EP
European Patent Office
Prior art keywords
protein
antigen
amino acid
acid sequence
neisserial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02777592A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1423419A2 (en
Inventor
Mariagrazia Chiron S.P.A. Pizza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Novartis Vaccines and Diagnostics SRL
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1423419(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK10179755.3T priority Critical patent/DK2327719T3/da
Priority to DK10179788.4T priority patent/DK2360176T3/en
Priority to EP14172613.3A priority patent/EP2829549A3/en
Priority to EP10179788.4A priority patent/EP2360176B1/en
Priority to EP10179755.3A priority patent/EP2327719B1/en
Application filed by Novartis Vaccines and Diagnostics SRL, Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics SRL
Publication of EP1423419A2 publication Critical patent/EP1423419A2/en
Publication of EP1423419B1 publication Critical patent/EP1423419B1/en
Application granted granted Critical
Priority to CY20111100383T priority patent/CY1113218T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is in the field of protein expression.
  • it relates to the expression of proteins from Neisseria (e.g. N.gonorrhoeae or, preferably, N.meningitidis ).
  • References 1 and 2 disclose alternative and improved approaches for the expression of the Neisserial proteins disclosed in references 3 to 6.
  • One such method is to produce 'hybrid' proteins in which two or more Neisserial proteins are expressed as a single polypeptide chain.
  • This approach offers two advantages. First, a protein that may be unstable or poorly expressed on its own can be assisted by adding a suitable hybrid partner that overcomes the problem. Second, commercial manufacture is simplified as only one expression and purification need be employed in order to produce two separately-useful proteins.
  • the invention provides a method for the simultaneous expression of two Neisserial proteins, in which said two or more proteins are joined such that they are translated as a single polypeptide chain.
  • the hybrid proteins of the invention can be represented by the formula: NH 2 -A-[-X-L-] n -B-COOH wherein X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is 2.
  • the 2 -X-moieties are 741, and ; or
  • a -X-moiety has a leader peptide sequence in its wild-type form, this may be included or omitted in described the hybrid proteins in full-length form, it is preferably at the C-terminal end of a hybrid protein; if it is to be used at the N-terminus, if is preferred to use a AG form of 741.
  • linker amino acid sequence -L- may be present or absent.
  • the hybrid may be NH 2 -X 1 -L 1 -X 2 -L 2 -COOH, NH 2 -X 1 -X 2 -COOH, NH 2 -X 1 -L 1 -X 2 COOH, NH 2 -X 1 -X 2 -L 2 -COOH, etc.
  • a useful linker is GSGGGG (SEQ ID 27), with the Gly-Ser dipeptide being formed from a Bam HI restriction site, thus aiding cloning and manipulation, and the Gly 4 tetrapeptide being a typical poly-glycine linker.
  • X n+1 is a ⁇ G protein and L n is a glycine linker, this may be equivalent to X n+1 , not being a ⁇ G protein and L n being absent.
  • -B- is an optional C-terminal amino acid sequence.
  • This will typically be short (e.g. 40 or fewer amino acids i.e . 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1).
  • Other suitable C-terminal amino acid sequences will be apparent to those skilled in the art.
  • the invention can use amino acid sequences from any strains of N.meningitidis. References to a particular protein therefore include that protein from any strain. Sequence variations between strains are included within (b)
  • Reference sequences from N.meningitidis serogroup B include:
  • sequence listing herein includes polymorphic forms of proteins 741 (SEQ IDs 1-22) and which have been identified:
  • Preferred proteins of the invention comprise -X- moieties having an amino acid sequence found in N.meningitidis serogroup B.
  • individual -X- moieties may be from one or more strains.
  • X 2 may be from the same strain as X 1 or from a different strain.
  • preferred -X- moieties are from strains 2996, MC58, 95N477, or 394/98.
  • Strain 95N477 is sometimes referred to herein as 'ET-37', this being its electrophoretic type.
  • Strain 394/98 is sometimes referred to herein as 'nz', as it is a New Zealand strain.
  • 741 is preferably from serogroup B strains MC58, 2996, 394/98, or 95N477, or from serogroup C strain 90/18311.
  • Strains are indicated as a subscript e.g. 741 MC58 is protein 741 from strain MC58. Unless otherwise stated, proteins mentioned herein (e.g. with no subscript) are from N.meningitidis strain 2996, which can be taken as a 'reference' strain. It will be appreciated, however, that the invention is not in general limited by strain. As mentioned above, general references to a protein may be taken to include that protein from any strain. This will typically have sequence identity to 2996 of 90% or more (eg. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more).
  • the invention also provides a protein having an amino acid sequence from SEQ IDs 1 to 22. It also provides proteins and nucleic acid having sequence identity to these. As described above, the degree of 'sequence identity' is greater than 90%,
  • the invention provides nucleic acid encoding such proteins.
  • the invention also provides nucleic acid encoding proteins according to the invention.
  • nucleic acid comprising sequences complementary to those described above (eg . for antisense or probing purposes).
  • Nucleic acid according to the invention can, of course, be prepared in many ways ( eg . by chemical synthesis, from genomic or cDNA libraries, from the organism itself etc.) and can take various forms (eg. single stranded, double stranded, vectors, probes etc.).
  • nucleic acid includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) etc.
  • the invention also provides a composition comprising two or more ( i.e . 2, 3, 4, 5. 6 or 7) of the following proteins:
  • the mixture may include one or both of the following proteins, either in combination with two or more of (I) to (7), or in combination with only one of (1) to (7):
  • a preferred mixture comprises the following three proteins:
  • the present invention preferably utilises a heterologous host.
  • the heterologous host may be prokaryotic (e.g . a bacterium) or eukaryotic. It is preferably E.coli, but other suitable hosts include Bacillus subtilis, Vibrio cholerae, Salmonella typhi, Salmonenna typhimurium, Neisseria lactamica, Neisseria cinerea, Mycobacteria ( e.g. M.tuberculosis ), yeast etc.
  • the invention provides (a) nucleic acid encoding the proteins described above (b) vectors comprising these nucleic acid sequences (c) host cells containing said vectors (d) compositions comprising the proteins or nucleic acids of the invention, which may be suitable as immunogenic compositions (e.g . vaccines) or as diagnostic reagents (e) these compositions for use as medicaments ( e.g .
  • compositions for treating or preventing infection due to Neisserial bacteria
  • diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisseria bacteria
  • a reagent which can raise antibodies against Neisseria bacteria for detecting the presence of Neisserial bacteria or of antibodies raised against Neisseria bacteria
  • a method of treating a patient comprising administering to the patient a therapeutically effective amount of these compositions.
  • Implementing the invention will typically involve the basic steps of: obtaining a first nucleic acid encoding a first protein; obtaining a second nucleic acid encoding a second protein; and ligating the first and second nucleic acids.
  • the resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector.
  • purification of hybrid proteins may involve the refolding techniques disclosed herein.
  • compositions of the invention are preferably immunogenic composition, and are more preferably vaccine compositions.
  • the pH of the composition is preferably between 6 and 7.
  • the pH may be maintained by the use of a buffer.
  • the composition may be sterile.
  • Vaccines according to the invention may either be prophylactic (i.e . to prevent infection) or therapeutic (i.e . to treat infection), but will typically be prophylactic.
  • the invention also provides a composition of the invention for use as a medicament.
  • the medicament is preferably able to raise an immune response in a mammal ( i.e . it is an immunogenic composition) and is more preferably a vaccine.
  • the invention also provides the use of a composition of the invention in the manufacture of a medicament for raising an immune response in a mammal.
  • the medicament is preferably a vaccine.
  • the invention also provides a method for raising an immune response in a mammal comprising the step of administering an effective amount of a composition of the invention.
  • the immune response is preferably protective.
  • the method may raise a booster response.
  • the mammal is preferably a human.
  • the human is preferably a child (e.g. a toddler or infant); where the vaccine is for prophylactic use, the human is preferably an adult.
  • a vaccine intended for children may also be administered to adults e.g . to assess safety, dosage, immunogenicity, etc.
  • These uses and methods are preferably for the prevention and/or treatment of a disease caused by a Neisseria (e.g. meningitis, septicaemia, gonorrhoea etc.).
  • a Neisseria e.g. meningitis, septicaemia, gonorrhoea etc.
  • the prevention and/or treatment of bacterial meningitis is preferred.
  • composition of the invention will typically, in addition to the components mentioned above, comprise one or more pharmaceutically acceptable carriers', which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition.
  • Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose ( WO00/56365 ) and lipid aggregates (such as oil droplets or liposomes).
  • Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, trehalose ( WO00/56365 ) and lipid aggregates (such as oil droplets or liposomes).
  • trehalose WO00/56365
  • lipid aggregates such as oil droplets or liposomes.
  • Such carriers are well known to those of ordinary skill in the art.
  • the vaccines
  • Immunogenic compositions used as vaccines comprise an immunologically effective amount of antigen, as well as any other of the above-mentioned components, as needed.
  • 'immunologically effective amount' it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, age, the taxonomic group of individual to be treated ( e.g . non-human primate, primate, etc.), the capacity of the individual's immune system to synthesise antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors.
  • Dosage treatment may be a single dose schedule or a multiple dose schedule ( e.g . including booster doses).
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • the vaccine may be administered in conjunction with other immunoregulatory agents.
  • the composition may include other adjuvants in addition to (or in place of) the aluminium salt.
  • Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59TM ( WO90/14837 Chapter 10 in ref.
  • RibiTM adjuvant system Ribi Immunochem, Hamilton, MT
  • MPL monophosphorylipid A
  • TDM trehalose dimycolate
  • CWS cell wall skeleton
  • saponin adjuvants such as QS21 or Stimulon TM
  • cytokines such as interleukins (e.g. IL-1. IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 ( WO99/44636 ), etc .), interferons (e.g . gamma interferon), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc .; (5) monophosphoryl lipid A (MPL) or 3-0-deacytated MPL (3dMPL) e.g .
  • MPL monophosphoryl lipid A
  • 3dMPL monophosphoryl lipid A
  • GB-2220221 EP-A-0689454 ; (6) combinations of 3dMPL with, for example, QS21 and/or oil-in-water emulsions e.g. EP-A-0835318 , EP-A-0735898 , EP-A-0761231 ; (7) oligonucleotides comprising CpG motifs [ Krieg Vaccine 2000, 19, 618-622 ; Krieg Curr- opin Mol Ther 2001 3:15-24 ; Roman et al., Nat. Med., 1997, 3, 849-854 ; Weiner et al., PNAS USA, 1997, 94, 10833-10837 ; Davis et al., J.
  • WO99/52549 (9) a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol ( e.g . WO01/21207 ) or a polyoxyethylene alkyl ether or ester surfactant in combination with at least one additional nonionic surfactant such as an octoxynol ( e . g . WO01/21152 ); (10) an immunostimulatory oligonucleotide (e . g . a CpG oligonucleotide) and a saponin e.g . WO00/62800 ; (11) an immunostimulant and a particle of metal salt e . g .
  • WO00/23105 (12) a saponin and an oil-in-water emulsion e.g ., WO99/11241 ; (13) a saponin ( e.g. QS21) + 3dMPL + lL-12 (optionally + a sterol) e . g . WO98/57659 ; (14) other substances that act as immunostimulating agents to enhance the efficacy of the composition.
  • Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nonnuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl- sn -glycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.
  • thr-MDP N-acetyl-muramyl-L-threonyl-D-isoglutamine
  • nor-MDP N-acetyl-nonnuramyl-L-alanyl-D-isoglutamine
  • N-MDP N-acetylmuramyl-L-alanyl-D-isoglutaminy
  • composition of the invention include:
  • composition may comprise one or more of these further antigens.
  • a saccharide or carbohydrate antigen is used, it is preferably conjugated to a carrier protein in order to enhance immunogenicity [ e.g . refs. 54 to 63].
  • Preferred carrier proteins are bacterial toxins or toxoids, such as diphtheria or tetanus toxoids.
  • the CRM 197 diphtheria toxoid is particularly preferred.
  • Other suitable carrier proteins include the N.meningitidis outer membrane protein [ e.g . ref. 64], synthetic peptides [ e . g . 65, 66], heat shock proteins [ e . g . 67], pertussis proteins [ e . g .
  • a mixture comprises capsular saccharides from both serogroups A and C
  • the ratio (w/w) of MenA saccharide:MenC saccharide is greater than 1 (e.g. 2:1, 3:1, 4:1, 5:1, 10: or higher). Saccharides from different serogroups of N.meningitidis may be conjugated to the same or different carrier proteins.
  • Toxic protein antigens may be detoxified where necessary (e . g . detoxification of pertussis toxin by chemical and/or genetic means [32]).
  • diphtheria antigen is included in the composition it is preferred also to include tetanus antigen and pertussis antigens. Similarly, where a tetanus antigen is included it is preferred also to include diphtheria and pertussis antigens. Similarly, where a pertussis antigen is included it is preferred also to include diphtheria and tetanus antigens.
  • Antigens are preferably mixed with (and more preferably adsorbed to) an aluminium salt (e.g. phosphate, hydroxide, hydroxyphosphate, oxyhydroxide, orthophosphate, sulphate).
  • the salt may take any suitable form (e.g. gel, crystalline, amorphous etc.).
  • Antigens in the composition will typically be present at a concentration of at least 1 ⁇ g/ml each. In general, the concentration of any given antigen will be sufficient to elicit an immune response against that antigen.
  • nucleic acid encoding the antigen may be used [ e.g . refs. 72 to 80]. Protein components of the compositions of the invention may thus be replaced by nucleic acid (preferably DNA e.g. in the form of a plasmid) that encodes the protein.
  • composition comprising X may consist exclusively of X or may include something additional e.g. X + Y.
  • Hybrid proteins - X 1 961c or 961cL
  • Titres obtained after immunisation with 961c-741 [refs. 1 & 2] were as follows: Strain (scrogroup) 2996 (B) MC58 (B) 394/98 (B) 44176 (B) F6124 (A) BZ133 (C) Al hydroxide 65536 32768 4096 >32768 16384 >2048 FCA >16384 262144 4096 >16384 - >2048
  • Results obtained after immunisation with proteins disclosed in refs. 1 & 2 were as follows: n X 1 L 1 X 2 L 2 Bactericidal titre ELISA FCA Alum FCA Alum 2 ORF46.1 - 961 (His) 6 8192 8192 21558 >109350 - 961 c (His) 6 8192 128 9020 76545
  • Titres using protein #4 were as follows: Strain (serogroup) 2996 (B) MC58 (B) 394198 (B) 44/76 (B) F6124 (A) Al hydroxide 256 >262144 >2048 32768 8192 FCA 1024 >262144 >2048 >32768 >32768
  • Titres using protein #7 were as follows: Strain (serogroup) 2996 (B) MC58 (B) 394/98 (B) 44/76 (B) F6124 (A) BZ133 (c) Al hydroxide 256 130000 16000 32000 8000 16000
  • mice were immunised with of three proteins adjuvanted with aluminium hydroxide, either single or in a triple combination: (1) 287 Nz -953; (2) 936-741; and (3) 961c.
  • the mixture was able to induce high bactericidal titres against various strains: 2996 (B) MC58 (B) NGH38 394/98 (B) H44/76 (B) F6124 (A) BZ133 (C) C11 (C) (1) 32000 16000 130000 16000 32000 8000 16000 8000 (2) 256 131000 128 16000 32000 8000 16000 ⁇ 4 (3) 32000 8000 - - 8000 - 32000 mix 32000 32000 65000 16000 260000 65000 >65000 8000 (X) 4000 4000 1000 1000 >4000 1000 4000 n.d. '-' indicates that this strain contains no NadA gene (X) was a combination of protein 287 with outer membrane vesicles, for comparison

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02777592A 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins Expired - Lifetime EP1423419B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK10179788.4T DK2360176T3 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserialt derived proteins
EP14172613.3A EP2829549A3 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179788.4A EP2360176B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179755.3A EP2327719B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
DK10179755.3T DK2327719T3 (da) 2001-09-06 2002-09-06 Hybrid- og tandemekspression af neisseria-proteiner
CY20111100383T CY1113218T1 (el) 2001-09-06 2011-04-15 Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121591 2001-09-06
GBGB0121591.2A GB0121591D0 (en) 2001-09-06 2001-09-06 Hybrid and tandem expression of neisserial proteins
PCT/IB2002/003904 WO2003020756A2 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins

Related Child Applications (5)

Application Number Title Priority Date Filing Date
EP14172613.3A Division EP2829549A3 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179755.3A Division EP2327719B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
EP10179788.4A Division EP2360176B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179755.3 Division-Into 2010-09-25
EP10179788.4 Division-Into 2010-09-26

Publications (2)

Publication Number Publication Date
EP1423419A2 EP1423419A2 (en) 2004-06-02
EP1423419B1 true EP1423419B1 (en) 2011-01-19

Family

ID=9921633

Family Applications (4)

Application Number Title Priority Date Filing Date
EP02777592A Expired - Lifetime EP1423419B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
EP10179755.3A Revoked EP2327719B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
EP14172613.3A Withdrawn EP2829549A3 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179788.4A Expired - Lifetime EP2360176B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP10179755.3A Revoked EP2327719B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial proteins
EP14172613.3A Withdrawn EP2829549A3 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins
EP10179788.4A Expired - Lifetime EP2360176B1 (en) 2001-09-06 2002-09-06 Hybrid and tandem expression of neisserial derived proteins

Country Status (18)

Country Link
US (6) US8980277B2 (enExample)
EP (4) EP1423419B1 (enExample)
JP (4) JP4511832B2 (enExample)
CN (2) CN101260148B (enExample)
AT (1) ATE496063T1 (enExample)
AU (2) AU2002339217B2 (enExample)
BR (1) BR0212363A (enExample)
CA (1) CA2459816C (enExample)
CY (2) CY1113218T1 (enExample)
DE (1) DE60238993D1 (enExample)
DK (3) DK2360176T3 (enExample)
ES (3) ES2523365T3 (enExample)
GB (1) GB0121591D0 (enExample)
MX (2) MXPA04002216A (enExample)
NZ (3) NZ532115A (enExample)
PT (3) PT2360176E (enExample)
RU (2) RU2475495C2 (enExample)
WO (1) WO2003020756A2 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE20321889U1 (de) * 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
SI1670506T1 (sl) * 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0415160D0 (en) * 2004-07-06 2004-08-11 Chiron Srl Inhibitors of bacterial infection
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
EP1962902A2 (en) * 2005-12-06 2008-09-03 Universita Degli Studi di Padova Methods and compositions relating to adhesins as adjuvants
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EA018068B1 (ru) 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
AU2009223613B2 (en) * 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
WO2009150531A1 (en) * 2008-06-09 2009-12-17 Novartis Ag Antibodies against neisserial factor h binding protein
EP2367568A2 (en) * 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010127172A2 (en) * 2009-04-30 2010-11-04 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) and methods of use
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
ES2596653T3 (es) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Ensayos bactericidas de opsonización y dependientes de anticuerpo mediado por el complemento de alto rendimiento
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
JP5363381B2 (ja) * 2010-03-09 2013-12-11 パナソニック株式会社 プラズマディスプレイパネル
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
CN102028941B (zh) * 2011-02-11 2013-02-13 中国医学科学院医学生物学研究所 一种b群脑膜炎球菌重组蛋白嵌合疫苗及其制备方法
US20140186861A1 (en) * 2011-07-11 2014-07-03 Uvic Industry Partnerships Inc. Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
BR112016002150A2 (pt) * 2013-08-02 2017-09-12 Children´S Hospital & Res Center At Oakland proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
KR102761870B1 (ko) 2014-07-23 2025-02-05 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 인자 h 결합 단백질 변이체 및 이의 사용 방법
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3211240A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1260858A (en) * 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
WO1991008772A1 (en) * 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2105382C (en) 1991-03-14 1999-01-19 Neil Goldstein Recombinant hybrid porin epitopes
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
RU2074728C1 (ru) * 1993-01-03 1997-03-10 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова РАМН Липополисахарид из neisseria meningitidis, обладающий протективными и иммуногенными свойствами
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP1029052B1 (en) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
ES2278420T3 (es) 1997-11-21 2007-08-01 Serono Genetics Institute S.A. Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion.
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
KR100627590B1 (ko) * 1998-01-30 2006-09-25 다이이치 아스비오파마 가부시키가이샤 보조 펩타이드를 사용하는 펩타이드의 제조방법
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2004511201A (ja) * 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
EP1123403A1 (en) * 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
BR0010721A (pt) 1999-05-19 2002-06-11 Chiron Spa Composições de neisserias combinadas
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
CA2871789C (en) * 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
EP1252182B1 (en) 2000-01-25 2012-06-20 The University Of Queensland PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
US20040167058A1 (en) * 2000-06-29 2004-08-26 Colgate-Palmolive Company Multi-phase clear fabric softening composition
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE20321889U1 (de) * 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DK2353608T3 (da) * 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
DK1587537T3 (da) * 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
KR20060019515A (ko) 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
SI1670506T1 (sl) * 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
SI2682126T1 (sl) 2005-01-27 2017-03-31 Children's Hospital & Research Center At Oakland Cepiva na osnovi veziklov, osnovanih na GNA1870, za širokospektralno zaščito proti boleznim, povzročenim z Neisserio meningitidisom
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
ES2555786T3 (es) 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
CA2756522C (en) * 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
ES2759484T3 (es) 2010-09-10 2020-05-11 Glaxosmithkline Biologicals Sa Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo

Also Published As

Publication number Publication date
CA2459816A1 (en) 2003-03-13
CA2459816C (en) 2014-06-10
BR0212363A (pt) 2004-08-10
AU2002339217B2 (en) 2008-09-04
US9056075B2 (en) 2015-06-16
WO2003020756A2 (en) 2003-03-13
CN101260148A (zh) 2008-09-10
NZ537976A (en) 2008-03-28
GB0121591D0 (en) 2001-10-24
US20110250223A1 (en) 2011-10-13
RU2004110230A (ru) 2005-04-20
RU2475495C2 (ru) 2013-02-20
NZ547145A (en) 2008-06-30
US20150273044A1 (en) 2015-10-01
EP2327719B1 (en) 2014-08-20
ATE496063T1 (de) 2011-02-15
RU2008122435A (ru) 2009-12-10
AU2008234959B2 (en) 2012-05-17
JP2005508156A (ja) 2005-03-31
MXPA04002216A (es) 2005-02-17
PT2327719E (pt) 2014-12-02
CY1117065T1 (el) 2017-04-05
DK2327719T3 (da) 2014-11-03
EP2360176A2 (en) 2011-08-24
NZ532115A (en) 2005-04-29
RU2339646C2 (ru) 2008-11-27
US20140294886A1 (en) 2014-10-02
DK2360176T3 (en) 2015-12-14
JP4511832B2 (ja) 2010-07-28
CY1113218T1 (el) 2016-04-13
US9011869B2 (en) 2015-04-21
EP2327719A1 (en) 2011-06-01
EP2829549A3 (en) 2015-06-03
EP2829549A2 (en) 2015-01-28
PT2360176E (pt) 2016-01-11
US20120195919A1 (en) 2012-08-02
JP2005350486A (ja) 2005-12-22
JP2010252807A (ja) 2010-11-11
ES2357503T3 (es) 2011-04-27
US8980277B2 (en) 2015-03-17
EP2360176A3 (en) 2012-01-18
US20180169210A1 (en) 2018-06-21
JP5542276B2 (ja) 2014-07-09
US20050222385A1 (en) 2005-10-06
WO2003020756A3 (en) 2003-11-20
EP1423419A2 (en) 2004-06-02
ES2556770T3 (es) 2016-01-20
DK1423419T3 (da) 2011-04-04
ES2523365T3 (es) 2014-11-25
PT1423419E (pt) 2011-03-10
CN101260148B (zh) 2012-05-09
AU2008234959A1 (en) 2008-11-13
US8840907B2 (en) 2014-09-23
CN1582297A (zh) 2005-02-16
DE60238993D1 (de) 2011-03-03
CN100390196C (zh) 2008-05-28
JP2014051497A (ja) 2014-03-20
MX336118B (es) 2016-01-08
EP2360176B1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
EP1423419B1 (en) Hybrid and tandem expression of neisserial proteins
EP1409013B1 (en) Vaccines comprising aluminium adjuvants and histidine
US20100233205A1 (en) Adjuvanted antigenic meningococcal compositions
EP2168597A1 (en) Vaccines comprising aluminium adjuvants and histidine
AU2002339217A1 (en) Hybrid and tandem expression of Neisserial proteins
AU2012202488B2 (en) Hybrid and tandem expression of Neisserial proteins
AU2014201962B2 (en) Hybrid and tandem expression of Neisserial proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040323

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20060825

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60238993

Country of ref document: DE

Date of ref document: 20110303

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60238993

Country of ref document: DE

Effective date: 20110303

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20110302

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2357503

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110427

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110400613

Country of ref document: GR

Effective date: 20110412

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 9189

Country of ref document: SK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20111020

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60238993

Country of ref document: DE

Effective date: 20111020

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20120829

Year of fee payment: 11

REG Reference to a national code

Ref country code: EE

Ref legal event code: AA1Y

Ref document number: E005330

Country of ref document: EE

Free format text: PRODUCT NAME: REKOMBINANTNE B-GRUPI NEISSERIA MENINGITIDIS'E;REG NO/DATE: K(2013)218 (LOPLIK) 14.01.2013

Spc suppl protection certif: C20130019

Filing date: 20130710

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCF

Free format text: PRODUCT NAME: REKOMBINANTNY FUZNY PROTEIN FHBP NEISSERIE MENINGITIDIS SKUPINY B; NAT. REGISTRATION NO/DATE: EU/1/12/812/001 - EU/1/12/812/004 20130114; FIRST REGISTRATION: EU EU/1/12/812/001 - EU/1 /12/812/004 20130114

Spc suppl protection certif: 7-2013

Filing date: 20130712

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG1Y

Ref document number: E005330

Country of ref document: EE

Free format text: PRODUCT NAME: REKOMBINANTNE B-GRUPI NEISSERIA MENINGITIDIS'E;REG NO/DATE: K(2013)218 (LOPLIK) 14.01.2013

Spc suppl protection certif: C20130019 00087

Filing date: 20130710

Extension date: 20270906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130930

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCG

Free format text: PRODUCT NAME: REKOMBINANTNY FUZNY PROTEIN FHBP NEISSERIE MENINGITIDIS SKUPINY B; NAT. REGISTRATION NO/DATE: EU/1/12/812/001 - EU/1/12/812/004 20130114; FIRST REGISTRATION: EU EU/1/12/812/001 - EU/1 /12/812/004 20130114

Spc suppl protection certif: 147 7-2013

Filing date: 20130712

Extension date: 20270907

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E005330

Country of ref document: EE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.; BE

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.

Effective date: 20170503

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60238993

Country of ref document: DE

Representative=s name: BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBB -, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 60238993

Country of ref document: DE

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A., BE

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIENA, IT

Ref country code: DE

Ref legal event code: R082

Ref document number: 60238993

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 9189

Country of ref document: SK

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A., RIXENSART, BE

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIENA (SI), IT

Effective date: 20170524

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20170921 AND 20170927

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20170904

Year of fee payment: 16

Ref country code: CH

Payment date: 20170725

Year of fee payment: 16

Ref country code: GR

Payment date: 20170828

Year of fee payment: 16

Ref country code: IT

Payment date: 20170914

Year of fee payment: 16

Ref country code: GB

Payment date: 20170829

Year of fee payment: 16

Ref country code: SK

Payment date: 20170830

Year of fee payment: 16

Ref country code: FR

Payment date: 20170823

Year of fee payment: 16

Ref country code: LU

Payment date: 20170914

Year of fee payment: 16

Ref country code: FI

Payment date: 20170828

Year of fee payment: 16

Ref country code: CZ

Payment date: 20170830

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20170703

Year of fee payment: 16

Ref country code: DK

Payment date: 20170828

Year of fee payment: 16

Ref country code: AT

Payment date: 20170828

Year of fee payment: 16

Ref country code: SE

Payment date: 20170911

Year of fee payment: 16

Ref country code: TR

Payment date: 20170815

Year of fee payment: 16

Ref country code: IE

Payment date: 20170918

Year of fee payment: 16

Ref country code: PT

Payment date: 20170829

Year of fee payment: 16

Ref country code: NL

Payment date: 20170913

Year of fee payment: 16

Ref country code: BE

Payment date: 20170919

Year of fee payment: 16

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER AND PEDRAZZINI AG, CH

Ref country code: CH

Ref legal event code: PFA

Owner name: GSK VACCINES S.R.L., IT

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., IT

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

Effective date: 20171205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60238993

Country of ref document: DE

Representative=s name: HOFFMANN - EITLE PATENT- UND RECHTSANWAELTE PA, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20170928

Year of fee payment: 16

REG Reference to a national code

Ref country code: EE

Ref legal event code: HC1A

Ref document number: E005330

Country of ref document: EE

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: GSK VACCINES S.R.L.; IT

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE; FORMER OWNER NAME: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.

Effective date: 20180104

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20171004

Year of fee payment: 16

Ref country code: CY

Payment date: 20170823

Year of fee payment: 16

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA; BE

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.

Effective date: 20180309

REG Reference to a national code

Ref country code: SK

Ref legal event code: SPCT

Owner name: NOVARTIS AG, CH

Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS S. R. L., IT

Spc suppl protection certif: 147 7-2013

Effective date: 20180425

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 496063

Country of ref document: AT

Kind code of ref document: T

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A., BE

Effective date: 20180913

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60238993

Country of ref document: DE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E005330

Country of ref document: EE

Effective date: 20180930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20180930

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20181001

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 496063

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180906

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190306

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180907

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 9189

Country of ref document: SK

Effective date: 20180906

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180930

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190402

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20191030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180907

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180906